EXAS (EXAS)
Quantitative Summary
DeterministicFinancial health is average: Piotroski 6/9. DCF fair value of $59 implies 44% downside based on model assumptions.
Generated deterministically from quant metrics and financial statements. Not a recommendation.
Algorithmic Teardown
AI-GeneratedThe underlying economic engine presents a stark dichotomy between robust top-line expansion and deteriorating bottom-line efficiency. While revenue grows at 17.7% annually, the company generates negative operating leverage with a net margin of -6.4%, driving an ROIC spread that is deeply negative relative to capital costs. This erosion in profitability is mathematically evident in the DuPont decomposition: despite healthy asset turnover (0.55x) and moderate financial leverage (2.44x), the collapse in margins drags overall return on equity down to -8.7%. Although the Piotroski F-Score of 6/9 suggests reasonable operational stability, the Beneish M-Score of -2.86 indicates a low probability of earnings manipulation, yet it cannot offset the fundamental reality that current operations are destroying value rather than generating cash flow.
Valuation metrics reflect this disconnect between growth expectations and realized returns. The stock trades at a significant discount to its DCF-derived fair value of $59, implying roughly 43.9% downside from current levels if the model's assumptions hold true. This pricing gap stems largely from market skepticism regarding the sustainability of such high implied free cash flow growth (22.0% over ten years) in an environment where net margins remain deeply negative. The asset is currently priced with a distinct tilt toward future growth potential, evidenced by a Value Factor (HML) of -0.682 and weak Profitability Factor (RMW) scores at -0.144, suggesting the market has not yet fully discounted the risk that current profitability trends may persist or worsen before they improve.
Risk-adjusted performance data reveals significant divergence between raw alpha generation and factor-based consistency. The Fama-French Alpha stands at an impressive 18.35% annually, indicating strong outperformance relative to a standard benchmark over the measured period; however, this comes with notable exposure to specific risk factors. Specifically, the negative Value Factor score highlights that returns are being driven by growth characteristics rather than value premiums, while the weak Profitability Factor underscores the vulnerability of the firm's earnings quality. With insider flow remaining neutral at zero over the last 90 days, there is no clear signal from management regarding future capital allocation or confidence in turning the profitability tide, leaving investors to weigh high theoretical alpha against structural margin constraints and valuation headwinds.
Generated by LLM from quantitative data inputs. May contain inaccuracies. Not investment advice.
DCF Sandbox
InteractiveThe growth rate the market implicitly expects over the next 10 years to justify today's price. Compare with historical growth of 18% YoY revenue.
Sensitivity Matrix
| TG ↓ / WACC → | 8% | 10% | 12% |
|---|---|---|---|
| 2% | $74 | $52 | $39 |
| 3% | $88 | $59 | $43 |
| 4% | $109 | $68 | $48 |
Center = base case. Green = >10% upside, Red = >10% downside vs $104.91.
Pre-computed DCF: WACC=10.0%, terminal growth 3%. Fair value $59 (-43.9%). Not investment advice.
Price Chart with Moving Averages
Technical Setup
AI GeneratedThe current trading price of $104.91 for EXAS presents a technical snapshot that requires further context regarding its relationship to key moving averages, which are not provided in the available data set. Without knowing whether this level sits above or below short-term and long-term trend lines such as the 50-day or 200-day simple moving average, it is impossible to definitively characterize the prevailing momentum direction or identify if the asset is in an established uptrend or downtrend phase. The absence of these comparative metrics limits the ability to assess whether recent price action represents a continuation of historical trends or a potential reversal point based on standard trend-following methodologies. Regarding short-term momentum, the Relative Strength Index (RSI) data is also missing from the current information, preventing an evaluation of overbought or oversold conditions. Typically, RSI values above 70 might suggest extended upward pressure where correction risks are often monitored by analysts, while readings below 30 could indicate potential buying opportunities following a decline. Since these specific indicators are unavailable for EXAS at $104.91, no conclusion can be drawn about the immediate velocity of price movement or the strength behind recent gains and losses. To form a complete technical picture, additional data points regarding moving average crossovers and RSI levels would be necessary to synthesize a comprehensive view of market sentiment. Until such information is available, observers should note that the current price level exists in isolation from its
Quant Health Deep Dive
Profitability & Value Creation
DuPont Analysis — ROE Decomposition
Breaking down Return on Equity to see how the company generates its ROE — efficiency, margins, or leverage.
Balance Sheet Health
Earnings Surprise History
EPS estimates vs actuals for the most recent reported quarters. Source: yfinance.
Risk Profile
Sharpe = risk-adjusted return (higher is better). Max drawdown = largest peak-to-trough decline. 1,200+ trading days.
Underwater (Drawdown from Peak)
How far below the all-time high the price has been over time. Deeper = more pain for holders.
Rolling 60-Day Beta vs S&P 500 (VOO)
How the stock's sensitivity to market moves changes over time. β > 1 = more volatile than the market.
Fama-French 5-Factor Exposure
Academic factor model decomposition — what's really driving this stock's returns.
Fama-French 5-Factor Model. Data: Kenneth French Data Library. Regression over 3 years of daily returns.
Fundamentals
EXAS Institutional Volume Profile
252-day volume distribution by price level. The Point of Control (POC) marks — the price where the most institutional volume transacted — an implicit support/resistance floor.
The highest-volume price zone for EXAS over the past year sits near $100.02 (23% of 252-day volume). The current price of $104.91 trades 4.9% above this institutional floor — a sign of upside momentum, though a pullback to the POC zone is a common reversion target. The highly concentrated volume profile (23% at POC) indicates strong consensus on fair value — institutional participants have repeatedly transacted near this price.
Volume Profile computed from 252 trading days of OHLCV data. Volume allocated to price bins proportionally based on daily high-low range. Not investment advice.
EXAS Capital Efficiency
How efficiently does EXAS convert operating profits into free cash? The FCF Conversion ratio measures the gap between accounting earnings and real cash generation.
EXAS converts 680% of its EBITDA into free cash flow, an exceptional conversion rate indicating an asset-light business model with minimal capital reinvestment drag.
Capital efficiency = Free Cash Flow ÷ EBITDA. Reinvestment = (EBITDA − FCF) ÷ EBITDA. Metrics from latest annual filings. Not investment advice.
Fails-to-Deliver (FTD) History
SEC-reported settlement failures. Elevated FTDs can indicate high short-selling pressure, operational settlement issues, or naked shorting activity.
| Date | Failed Shares | Close Price | Notional Value |
|---|---|---|---|
| 2026-03-24 | 2,099 | $104.91 | $220,206.09 |
| 2026-03-23 | 6,494 | $104.91 | $681,285.54 |
| 2026-03-03 | 55,749 | $103.35 | $5.8M |
| 2026-02-13 | 20,470 | $103.23 | $2.1M |
| 2026-01-20 | 4,513 | $102.43 | $462,266.59 |
| 2026-01-16 | 37 | $102.34 | $3,786.58 |
| 2026-01-15 | 1,446 | $102.26 | $147,867.96 |
| 2026-01-14 | 508 | $102.25 | $51,943 |
| 2026-01-09 | 3 | $101.78 | $305.34 |
| 2025-12-30 | 4,813 | $101.93 | $490,589.09 |
| 2025-12-23 | 557,190 | $101.82 | $56.7M |
| 2025-12-16 | 34 | $101.74 | $3,459.16 |
| 2025-12-04 | 67 | $101.25 | $6,783.75 |
| 2025-12-03 | 2,309 | $101.20 | $233,670.8 |
| 2025-12-02 | 209 | $101.20 | $21,150.8 |
| 2025-11-26 | 9,100 | $101.13 | $920,283 |
| 2025-11-24 | 1,186 | $100.90 | $119,667.4 |
| 2025-11-21 | 19,786 | $100.67 | $2.0M |
| 2025-11-20 | 278 | $86.18 | $23,958.04 |
| 2025-11-17 | 100 | $67.03 | $6,703 |
| 2025-11-14 | 33,779 | $67.75 | $2.3M |
| 2025-11-12 | 9,076 | $67.50 | $612,630 |
| 2025-11-10 | 100 | $66.18 | $6,618 |
| 2025-11-06 | 13,471 | $69.63 | $937,985.73 |
| 2025-11-03 | 100 | $64.69 | $6,469 |
| 2025-10-28 | 242 | $63.50 | $15,367 |
| 2025-10-22 | 11,877 | $63.41 | $753,120.57 |
| 2025-10-20 | 1,628 | $61.23 | $99,682.44 |
| 2025-10-14 | 105,705 | $59.36 | $6.3M |
| 2025-10-10 | 195 | $59.46 | $11,594.7 |
Source: SEC Regulation SHO FTD data. Data is reported with a ~30 day delay. High FTD quantities relative to average daily volume may indicate settlement stress.
Price Correlations
Statistical correlation of daily returns with other stocks. High correlations indicate stocks that move together; negative correlations can offer diversification.
| Peer | 252-Day (1Y) | 126-Day (6M) | Direction |
|---|---|---|---|
| WTGXX | NaN | NaN | |
| ADPT | 0.353 | 0.328 | Moderate |
| GEHC | 0.320 | 0.222 | Moderate |
| MTD | 0.316 | 0.152 | Moderate |
| ISRG | 0.313 | 0.090 | Moderate |
| A | 0.310 | 0.152 | Moderate |
| NRIX | 0.304 | 0.271 | Moderate |
| NTRA | 0.302 | 0.205 | Moderate |
| CPT | 0.302 | 0.118 | Moderate |
| TXG | 0.299 | 0.124 | Low correlation |
Pearson correlation of daily log returns. 252d ≈ 1 trading year. Computed from price history. Not investment advice.
Compare EXAS to Peers
Quant metrics computed deterministically from financial statements and price data. Updated: 2026-03-23.
SecuritiesDB provides programmatic data aggregation for informational purposes only. None of the metrics, summaries, or algorithmic flags constitute a recommendation to buy or sell any security.